Date: 2016-01-21
Type of information: Exercise of an option agreement
Compound: empowered antibodies including antibody drug conjugates
Company: Pfizer (USA - NY) Philogen (Italy)
Therapeutic area:
Type agreement: R&D licensing
Action mechanism: antibody drug conjugate (ADC)
Disease:
Details: * On December 22, 2014. Philogen, a biotechnology company developing antibody and small molecule targeted therapies, announced that it has entered in to an option and license agreement with Pfizer Inc. to develop and commercialise multiple ‘empowered antibodies’. Philogen brings to the partnership validated antibodies with precise specificity in certain diseases characterised by angiogenesis. ‘ This new initiative combines Philogen’s validated antibodies with Pfizer’s extensive chemistry and clinical capabilities, and aims to accelerate the potential development of novel Antibody Drug Conjugates (ADCs) into the clinic.” commented Dr. Duccio Neri, Philogen’s CEO.
Under the terms of the agreement, Pfizer has exclusive rights to pursue development of certain ADCs and guided nanoparticles. Pfizer will be responsible for research and development and potential commercialization of candidate molecules. In January 2013, Philogen and Pfizer entered into an exclusive license agreement regarding the 'armed antibody' Dekavil, under which Pfizer is exploring the activity of Dekavil for autoimmune diseases.
Financial terms:
Latest news: * On January 21, 2016. Philogen announced that Pfizer has exercised options granted under the agreement established in December 2014 for the potential development and commercialization of multiple antibody drug conjugates. Pfizer now has exclusive rights to pursue development of certain ADCs and targeted technologies
and is responsible for research and development and potential commercialization of candidate molecules.
